Department of Medicine
 

About Us

The Ponce CRS, one of the four clinical research sites of the Emory-CDC HIV/AIDS Clinical Trials Unit, is part of the Ponce De Leon Center, an HIV care clinic within the Grady Health System that serves diverse and underrepresented minority populations.

The unit is also a part of the Emory Center for AIDS Research (CFAR) Clinical Research Core, a research group within Emory University that conducts NIH-funded HIV/AIDS research.

Key Research Areas

The Ponce Clinical Research Site (CRS) began conducting HIV/AIDS studies as part of the NIH-funded AIDS Clinical Trials Group (ACTG) in 1996. Since then, more than 500 patients with HIV have participated in these trials.

The Ponce CRS began conducting studies as part of the NIH-funded HIV Prevention Trials Network (HPTN) in 2009. Since then, more than 400 individuals at risk for HIV have participated in these trials. 

The mRNA-1273 vaccine was developed to prevent COVID-19. The purpose of this study was to test Moderna’s COVID-19 vaccine candidate to see if it can prevent illness if people are exposed to the SARS-CoV-2 virus in their everyday lives. 

CTG Investigator Carlos Del Rio and his team at the Ponce CRS prove you can still have fun with your mask on.

Research News

In July 2020, REPRIEVE held its first-ever Virtual Meeting with nearly 300 virtual attendees! Attendees heard a keynote presentation from Dr. Sandra Wanger Cordoso on HIV and CVD risk in Brazil, and 3 additional presentations from REPRIEVE Co-Investigators Dr. Kristine Erlandson, Dr. Turner Overton, and Dr. Carl Fichtenbaum. Presenters discussed their findings from their respective manuscripts in the JID supplement.

Other News of Interest

COVID-19 News Updates

On March 18, the Healthcare Leadership Collaborative brought together leaders and professionals from across the nation to advocate for health care workers’ well-being and mental health.

A recent study by Emory University researchers provides new insights into why the mRNA vaccines developed to fight COVID-19 in 2021 are less effective in patients with autoimmune diseases.

New research from Emory University is providing a more precise prediction of COVID-19 severity that can be found by looking at autoantibodies in the nasal cavity, leading to more personalized treatment plans.